Endo International plc (ENDP - Free Report) announced positive data from a phase IIb study on Xiaflex (collagenase clostridium histolyticum) for the treatment of patients suffering from edematous fibrosclerotic panniculopathy, also known as cellulite.
Data showed that patients treated with Xiaflex experienced a statistically significant improvement in the primary endpoint of composite investigators' and patients' assessments of the appearance of cellulite, compared to those treated with placebo. The study also met all the secondary endpoints. On the safety front, Xiaflex was found to be well tolerated.
Based on the encouraging study results, Endo plans to work with the FDA to advance Xiaflex as a cellulite treatment into late-stage development.
As per the company’s press release, there is currently no FDA-approved pharmacological treatment despite multiple therapeutic approaches for the attempted treatment of cellulite.
We note that Xiaflex is currently approved in the U.S. and the EU for the treatment of Dupuytren's contracture in adult patients with a palpable cord, and Peyronie's disease in adult men with a palpable plaque and penile curvature deformity of at least 30 degrees at the start of therapy. Xiaflex enjoys Orphan Drug status for both the indications in the U.S.
Endo currently carries a Zacks Rank #3 (Hold).
ENDO INTL PLC Price
Stocks to Consider
Some better-ranked stocks in the healthcare sector include Incyte Corporation (INCY - Free Report) , Anika Therapeutics (ANIK - Free Report) and Exelixis, Inc. (EXEL - Free Report) . All the three stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Incyte’s earnings estimates increased from 20 cents to 68 cents for 2016 and from $1.42 to $1.70 for 2017 over the last 60 days. The company posted a positive average beat of 431.43% over the last four quarters.
Anika’s earnings estimates increased from $1.96 to $2.06 for 2016 and from $2.03 to $2.09 for 2017 over the last 60 days. The company posted a positive surprise in all of the four trailing quarters with an average beat of 33.14%. Its share price has gained 18.2% year to date.
Exelixis’ loss estimates narrowed from 65 cents to 51 cents for 2016 and from 7 cents to earnings of 4 cents for 2017 over the last 60 days. The company posted a positive surprise thrice in the four trailing quarters with an average beat of 38.52%. Its share price has skyrocketed above 150% year to date.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>